Monoclonal antibodies: current and future potential

ESH eLearning, Saad Usmani, 234050

Targeting BCMA with bispecific antibodies in R/R myeloma

ESH eLearning, Saad Usmani, 234051

Updated POLLUX results for early relapsed myeloma patients

ESH eLearning, Saad Usmani, 234052

UK NCRI AML17 trial update: everolimus addition for consolidation

ESH eLearning, Robert Hills, 234049

Mapping the genomic landscape of Waldenström’s Macroglobulinemia

ESH eLearning, Steven Treon, 234055

Exploring treatment options against different Waldenström’s mutations

ESH eLearning, Steven Treon, 234054

Whole genome sequencing opens door for targeted Waldenström’s therapy

ESH eLearning, Steven Treon, 234053

Early detection and intervention in myeloma: a critical point

ESH eLearning, Jesús San Miguel, 234024

Continuous vs. fixed duration therapy for multiple myeloma?

ESH eLearning, Jesús San Miguel, 234025

Future treatment combinations for myeloma

ESH eLearning, Kenneth Anderson, 234026

MRD detection in myeloma: approval of NGS assay & questions for the clinic

ESH eLearning, Kenneth Anderson, 234027

Frontline transplant-ineligible MM treatment

ESH eLearning, Kwee Yong, 234028

Combining bortezomib and lenalidomide-based regimens for frontline MM

ESH eLearning, Kwee Yong, 234029

Real world evidence: what is it and what can it tell us?

ESH eLearning, Kwee Yong, 234030

How should smoldering multiple myeloma be monitored?

ESH eLearning, María-Victoria Mateos, 234031

Update on recent smoldering multiple myeloma trials

ESH eLearning, María-Victoria Mateos, 234032

Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma

ESH eLearning, María-Victoria Mateos, 234033

Opinion: EU approval of daratumumab plus VMP for frontline transplant-ineligible multiple myeloma

ESH eLearning, María-Victoria Mateos, 234034

Plasma cell leukemia and extramedullary disease in multiple myeloma

ESH eLearning, Niels van de Donk, 234035

Daratumumab in myeloma update: expanding indications

ESH eLearning, Niels van de Donk, 234036

A novel mechanism of action for daratumumab in myeloma

ESH eLearning, Niels van de Donk, 234037

CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079

ESH eLearning, Niels van de Donk, 234038

MRD negativity using deep sequencing is a major prognostic factor in myeloma

ESH eLearning, Nikhil Munshi, 234039

MRD sequencing test approved for MM in the US

ESH eLearning, Nikhil Munshi, 234040

Genomics shed light on targeted treatment for myeloma

ESH eLearning, Nikhil Munshi, 234041

Frontline treatment of transplant-ineligible MM: a changing landscape

ESH eLearning, Noopur Raje, 234042

Quadruplet regimens and antibodies for newly diagnosed multiple myeloma

ESH eLearning, Noopur Raje, 234043

CAR T-cells for myeloma: an update

ESH eLearning, Noopur Raje, 234044

PVX-410 vaccine for smoldering myeloma

ESH eLearning, Noopur Raje, 234045

Precision medicine in multiple myeloma: BRAF, NRAS, KRAD, t(11;14)

ESH eLearning, Noopur Raje, 234046

Judging the value of a clinical trial in hem-onc

ESH eLearning, Robert Hills, 234047

Opinion: value of MRD as an endpoint in hem-onc clinical trials

ESH eLearning, Robert Hills, 234048

How to predict response in silico and in vitro?

ESH eLearning, David Weinstock, 234062

Design of innovative clinical trials: still a role for phase III trials?

ESH eLearning, Andrew J. Davies, 234063

Minimal biological measurement requirements for DLBCL: What do clinicians need to have measured?

ESH eLearning, Lisa RIMSZA, 234061

Diamond-Blackfan anaemia : genetic and clinical complexity exemplified by 3 cases encountered in clinical practice

ESH eLearning, Marcin Wlodarski, 265289

Inflammation as a determinant of ineffective erythropoiesis in myelodysplastic syndromes

ESH eLearning, Alan List, 265283

TGF-b pathway inhibitors in low risk MDS

ESH eLearning, Valeria Santini, 265284

New approches to managing sickle cell disease

ESH eLearning, David Rees, 265285

Heme regulation and GATA1

ESH eLearning, Janis Abkowitz, 265286

Gene editing for thalassemia and sickle cell disease

ESH eLearning, Daniel Bauer, 265287

Gene therapy for thalassaemia / sickle cell disease

ESH eLearning, Alexis A. Thompson, 265288

Autoimmune haemolytic anaemias

ESH eLearning, Wilma Barcellini, 265282

Fanconi anaemia

ESH eLearning, Carlo Dufour, 265281

Rational Targeting of the NuRD Complex For Fetal Hemoglobin Induction 2019 ESH Erythropoiesis

ESH eLearning, Daniel Bauer, 265280

Which pro-survival BCL-2 family member should be targeted for the treatment of which type of leukaemia or lymphoma

ESH eLearning, Andreas Strasser, 234057

Targeting MALT1 signaling: preclinical data and perspectives in the clinic

ESH eLearning, Daniel KRAPMANN, 234058

The genetic landscape of MCL – more than CyclinD1?

ESH eLearning, Eias CAMPO, 234059

T-NHL: novel targets and therapies - How can we move forward?

ESH eLearning, Norbert SCHMITZ, 234060

Promoter mutations associated with hereditary persistence of fetal haemoglobin either disrupt repressors or create de novo sites for activators

ESH eLearning, Merlin Crossley, 265279

The relationship between genome structure and function : lessons from the globin loci

ESH eLearning, Douglas HIGGS, 265278

Acute sickling crisis

ESH eLearning, Lucia De Franceschi, 265277

Sickle cell disease

ESH eLearning, Mariane de Montalembert, 265276

Hereditary haemolytic anaemias

ESH eLearning, Immacolata Andolfo, 265275

Clinical consequences of ineffective erythropoiesis in myelodysplastic syndromes

ESH eLearning, Aristoteles Giagounidis, 265274

Congenital dyserythropoietic anaemias

ESH eLearning, Roberta Russo, 265273

Congenital dyserythropoietic anaemias (CDAs)

ESH eLearning, Achille Iolascon, 265272

Transcription Factors in Erythropoiesis

ESH eLearning, John Strouboulis, 265271

Origin of mega/erythroid progenitors in haematopoiesis

ESH eLearning, Claus Nerlov, 265270

Managing CML in emerging regions: some problems and perspectives

ESH eLearning, Hemant Malhotra, 234664

Long-term survival of patients with chronic phase chronic myeloid leukemia who received autologous stem cell transplantation and further exposed to tyrosine kinase inhibitors

ESH eLearning, Mauricette Michallet, 234801

Treatment-free remission in patients with chronic phase chronic myeloid leukemia and stable deep molecular response discontinuing dasatinib (DASFREE)

ESH eLearning, Susanne Saussele, 257032

Long-term results of a phase 2 trial of nilotinib 400 Mg twice daily in newly diagnosed patients with chronic phase of chronic myeloid leukemia

ESH eLearning, Lucia Masarova, 257031

Patients' perspectives on the definition of cure in chronic myeloid leukemia: a US based survey

ESH eLearning, Gemlyn George, 257030

The technical decline in the rate of CML treatment-free remission in aging countries: the French experience

ESH eLearning, Marc Delord, 257017

Prevalence and outcomes of uncommon BCR-ABL fusion transcripts in patients with CML: data from a single center

ESH eLearning, Qian Jiang, 257018

Aim for the cure: TKI-based chemotherapy for Ph+ ALL

ESH eLearning, Elias Jabbour, 257019

Impact of kinase domain mutations on second line nilotinib therapy In CML chronic phase – Real world data from a developing country perspective

ESH eLearning, Shinto Francis Thekkudan, 234569

Molecular milestones using the BCR-ABL1 qPCR level and doubling time after imatinib discontinuation to predict successful treatment-free remission: treatment-free remission accomplished by dasatinib (TRAD) trial

ESH eLearning, Dennis KIM, 234573

Low-intensity TKI-based therapy for Ph+ ALL

ESH eLearning, Hervé Dombret, 234568

What prevents the disease from relapsing after TKI discontinuation

ESH eLearning, Satu Mustjoki, 234803

How to identify and manage Ph-like ALL

ESH eLearning, Sarah Tasian, 234798

Stem cell transplant for Ph+ ALL: who, when, how

ESH eLearning, Federico Lussana, 234797

Are TKI really safe?

ESH eLearning, Carlo Gambacorti-Passerini, 234570

Long-term impact of early and deeper molecular response in newly diagnosed CML-CP patients receiving radotinib: three years follow-up of rerise study

ESH eLearning, Young Rok Do, 234571

Loss of function of the SETD2 tumor suppressor is a recurrent event in advanced-phase chronic myeloid leukemia, is due to post-translational mechanisms and fosters genetic instability

ESH eLearning, Manuela Mancini, 257025

MDS/MPN: SENECTUS IPSA EST MORBUS?

ESH eLearning, Michael W Deininger, 257026

CML hematopoietic stem cells expressing IL-1RAP may be targets of chimeric antigen receptor (CAR) - engineered T-cells

ESH eLearning, Christophe Ferrand, 257027

A genome-scale CRISPR knock-out screen in chronic myeloid leukemia identifies common drug resistance mechanisms 

ESH eLearning, Matthieu Lewis, 257028

Modulation of p53 with the MDM2 antagonist idasanutlin, in combination with nilotinib treatment, targets primitive CML cells in vitro and in vivo.

ESH eLearning, David Vetrie, 257029

ELN and real-word treatment algorithms for MPNs

ESH eLearning, Giuseppe Saglio, 234566

The association of transposable elements with chronic myeloid leukemia supports an assumption that non-coding variable regions of the human genome may play a role in hematological malignancies

ESH eLearning, Jitka Koblihova, 234567

Single-molecule sequencing reveals patterns of pre-existing drug resistance that suggest treatment strategies in Philadelphia-positive leukemias

ESH eLearning, Justin Pritchard, 234802

Resistance and progression to TKI: not just mutations

ESH eLearning, Jerry Radich, 234800

Novel approaches to monitor MPN

ESH eLearning, Jerry Radich, 234799

Bcl-2 and its inhibition in leukemia

ESH eLearning, Marina Y. Konopleva, 234637

HMGCLL1 Is a predictive germline biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia

ESH eLearning, Dennis KIM, 234572

Spirit 2: final analysis of an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML

ESH eLearning, Stephen OBrien, 257021

Nilotinib vs. Nilotinib plus interferon α induction and nilotinib or interferon α maintenance therapy for newly diagnosed BCR-ABL positive. Chronic myeloid leukemia patients in chronic phase: interim analysis of the tiger (CML V) trial

ESH eLearning, Andreas Hochhaus, 257020

Minimal, measurable, atypical

ESH eLearning, Nick CROSS, 257024

Identification of metabolic vulnerabilities in leukemic stem cells using the integrative omic approach 

ESH eLearning, Zuzana Brabcova, 257023

TNFα-induced bone marrow stromal niche alterations enhance leukemic stem cell growth via CXCL1/CXCR2 signaling

ESH eLearning, Puneet Agarwal, 257022

Why the fuss over CML stem cells ?

ESH eLearning, Robert Peter GALE, 234565

Mastocytosis

ESH eLearning, Jason Gotlib, 219417

Are we using personalized treatment for patients with myelofibrosis?

ESH eLearning, Alessandro Vannucchi, 219254

Stem cell depletion therapy is needed to change the natural history of the MPNs

ESH eLearning, Ronald Hoffman, 219253

Dissecting the molecular genetics of MPN

ESH eLearning, Ann Mullally, 219252

Epigenetics in myeloproliferative neoplasms

ESH eLearning, Mary Frances McMullin, 219251

MPN Drivers: from active JAK2 and TpoR mutants to rogue calreticulin and their role in progression

ESH eLearning, Stefan Constantinescu, 219248

Somatic mutations and clonal relationships

ESH eLearning, Peter Campbell, 219247